e-learning
resources
London 2016
Sunday, 04.09.2016
Comorbidities and exacerbations in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Co-morbidities and pulmonary arterial hypertension (PAH) in COPD patients
Velin Stratev (Varna, Bulgaria), Velin Stratev, Tanya Dobreva, Valentina Dimitrova, Diana Petkova
Source:
International Congress 2016 – Comorbidities and exacerbations in COPD
Session:
Comorbidities and exacerbations in COPD
Session type:
Thematic Poster
Number:
1131
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Velin Stratev (Varna, Bulgaria), Velin Stratev, Tanya Dobreva, Valentina Dimitrova, Diana Petkova. Co-morbidities and pulmonary arterial hypertension (PAH) in COPD patients. Eur Respir J 2016; 48: Suppl. 60, 1131
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
NT-proBNP in assessment of pulmonary hypertension in COPD patients
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Conclusion: treatment of pulmonary hypertension in COPD patients
Source: Annual Congress 2005 - COPD - pulmonary haemodynamics and gas exchange
Year: 2005
Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension
Year: 2019
Impact of exacerbations on pulmonary arterial enlargement in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD): Preliminary data of a longitudinal survey
Source: International Congress 2014 – Clinical presentations
Year: 2014
COPD and clinical phenotypes: Patients with concomitant pulmonary hypertension may be less likely to be frequent exacerbators
Source: International Congress 2014 – Clinical presentations
Year: 2014
Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2003; 22: Suppl. 45, 427s
Year: 2003
The prevalence and characteristics of pulmonary hypertension in severe COPD
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Acute and chronic effects of PDE5-Is on SpO2 in patients with COPD associated pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Association between arterial stiffness and acute exacerbations in patients with chronic obstructive pulmonary disease
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019
Evidence of renal and pulmonary endothelial dysfunction in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) and COPD concomitant with bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 521s
Year: 2004
Secondary pulmonary hypertension in patients with COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 348s
Year: 2007
Pulmonary hypertension at the patients with bronchial asthma and COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 58s
Year: 2004
Influence of bronchodilators on pulmonary hypertension (PH) in patients with moderate and severe chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2005; 26: Suppl. 49, 310s
Year: 2005
Pulmonary hypertension in COPD
Source: Eur Respir J 2008; 32: 1371-1385
Year: 2008
Pulmonary hypertension in patients with COPD
Source: Eur Respir Mon 2012; 57: 138-147
Year: 2012
Impact of comorbidities on chronic obstructive pulmonary disease (COPD) exacerbations in Singapore
Source: International Congress 2015 – Clinical assessment in asthma and COPD
Year: 2015
Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept